Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

PRINCETON - Sonnet BioTherapeutics Holdings, Inc., a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today the publication of extensive preclinical data on...

Related Keywords

Pankaj Mohan ,Jack Yauch ,Securities Exchange ,Exchange Commission ,Sonnet Biotherapeutics Holdings Inc ,Nasdaq ,Secreted Protein Acidic ,Programed Death Ligand ,Fully Human Albumin Binding ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,News Publishing ,Markets ,